Compare
| A | B | A − B | |
|---|---|---|---|
| Patients | 30 | 170 | -140 |
| Mean treatment day | 112 | 111 | +1 |
| Strong responders | 0% | 100% | -100% |
| Discontinuation risk ≥ 70% | 0% | 0% | 0% |
| At risk | 0% | 1% | -1% |
| Tolerance deteriorating | 13% | 33% | -20% |
| GI unstable | 0% | 1% | -1% |
| Response today | 36 | 81 | -45 |
| GI burden today | 18 | 17 | +1 |
| Toxicity today | 15 | 15 | 0 |
| Adherence | 83% | 92% | -9% |
| Quality of life | 55 | 77 | -22 |
| Segment | A | B | A − B |
|---|---|---|---|
| FUT2 non-secretor | 67% | 26% | +41 pp |
| IL6 high-expression variant | 57% | 17% | +40 pp |
| Poor metabolizer | 20% | 16% | +4 pp |
| Low butyrate capacity | 63% | 1% | +62 pp |
| Low microbial diversity | 73% | 9% | +64 pp |
| Baseline state S14 | 10% | 8% | +2 pp |
| Cluster EC-03 (high response / high intolerance) | 0% | 0% | 0 pp |
| Adherence < 60% | 0% | 0% | 0 pp |
EC-01 · Delayed loss of response: 30 patients, mean day 112. 13% have deteriorating tolerance, 0% unstable GI, 0% carry ≥60% discontinuation risk; mean GI 18, adherence 83%. Dominant clusters: EC-01 100%.
Shared biology: Low microbial diversity 73%, FUT2 non-secretor 67%, Low butyrate capacity 63%, IL6 high-expression variant 57%. Dietary detractors: fat in 87%, simpleCarbs in 70%, histamine in 67%.
What worked: BR-03 improved 50% of 4; what did not: AD-05 improved only 33% of 6. By biology: AD-05 works best in Low microbial diversity (33%) and worst in FUT2 non-secretor (25%).
No learned rules apply yet; run learning after the first campaign results.
minResponseProbability 0.65: 170 patients, mean day 111. 33% have deteriorating tolerance, 1% unstable GI, 1% carry ≥60% discontinuation risk; mean GI 17, adherence 92%. Dominant clusters: SR 78%, EC-02 19%, MR 2%.
Shared biology: FUT2 non-secretor 26%. Dietary detractors: histamine in 29%, alcohol in 28%, simpleCarbs in 8%.
What worked: BR-03 improved 50% of 4.
No learned rules apply yet; run learning after the first campaign results.